Lawsuit for Investors in shares of Juno Therapeutics Inc announced by Shareholders Foundation

SAN DIEGO, Aug. 22, 2016 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in Washington on behalf of certain purchasers of shares of Juno Therapeutics Inc (NASDAQ:JUNO) over alleged Securities Laws Violations by Juno Therapeutics. The lawsuit seeks to recover damages for certain NASDAQ:JUNO investors.

Investors who purchased shares of Juno Therapeutics Inc (NASDAQ:JUNO) have certain options and for certain investors there are short and strict deadlines running. Deadline: September 12, 2016. NASDAQ:JUNO investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The plaintiff alleges that the defendants materially misled investors by failing to disclose the May 2016 death of a patient in the Company’s Phase 2 trial of product candidate JCAR015 and that these omissions led Juno to trade at artificially inflated prices, and certain insiders participated in the heavy selling of shares in the weeks prior to the disclosure of the death.

On July 7, 2016, Juno Therapeutics Inc announced that it has received notice from the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL), known as the “ROCKET” trial. Juno Therapeutics Inc said that the clinical hold was initiated after two patient deaths one week earlier, which followed the recent addition of fludarabine to the pre-conditioning regimen.

Those who purchased Juno Therapeutics Inc shares should contact the Shareholders Foundation, Inc. by e-mail at mail@shareholdersfoundation.com or call +1 (858) 779-1554.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 mail@shareholdersfoundation.com 3111 Camino Del Rio North Suite 423 San Diego, CA 92108

Source:Shareholders Foundation, Inc.